These upcoming presentations underscore the breadth and versatility of our ACT-UP1 platform,” said Xuehai Liang, Ph.D., Chief Executive Officer of Arnatar Therapeutics. “By demonstrating the ability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback